



The 43rd Annual
**High Country
Nuclear
Medicine
Conference**

March 5-8, 2022
Sun Valley Inn | Sun Valley, ID

Saturday, March 5, 2022

All session times are in Mountain Time

6:30 AM – 7:00 AM

Breakfast with the Vendors

Welcome: Kevin Donohoe

7:00 AM – 9:30 AM

Virtual & CE Session

The Present and Future of Nuclear Medicine in the Management of Prostate Cancer

Session Chair: Bitai Savir-Baruch, MD

Description: In this session, we will discuss the use of molecular imaging to diagnose and treat prostate cancer.

- Introduction of the current standard practice of prostate cancer imaging in primary and recurrent prostate cancer
- Understand the use pros and cons of fluciclovine and PSMA PET tracers in the staging and restaging of prostate cancer
- Overview of the PSMA therapeutics clinical trials performed in the world
- Understand the use of PSMA theranostics in the future clinical practice
- Application of all available modalities to the management of prostate cancer A-Z.

Scheduled Topics:

Session Introduction

Prostate Cancer Imaging Using Fluciclovine and PSMA PET Tracers

Chair: Bitai Savir-Baruch, MD

Diagnosis and Management of Metastatic Prostate Cancer- From Oligometastatic To Polymetastatic Disease

Speaker: Hossein Jadvar, MD, PhD, MPH, MBA

Prostate Cancers Theranostics: A True Game-Changer

Speaker: Jeremie Calais, MD, MSc

1:00 PM – 3:00 PM

Roundtable: General Oncology

Moderator: Michael Graham, PhD, MD

Scheduled Topics:

Thyroid Cancer - Recent Developments

TSH vs. Thyroid hormone withdrawal

Re-differentiation agents

Parotid massage

FAPI

Indications and Pitfalls
Clinical trials and Approval

4:00 PM – 7:30 PM

Therapeutic/Diagnostic Isotopes

Session Chair: Roy Brown, MBA

Description: Nuclear Medicine is seeing several new diagnostic and therapeutic radionuclides being used in clinical practice and clinical trials. Some of these radionuclides present challenges in their production and distribution, but offer advantages in patient access and therapeutic effectiveness. This session will address many of these new radionuclides and their potential impact on nuclear medicine.

Scheduled Topics:

So Many Radionuclides to Choose From

Speaker: Roy Brown, MBA

⁶⁴Cu for imaging - we have only seen the beginning

Speaker: Andreas Kjaer, MD, PhD

⁶⁷Cu Production on an Electron Beam Accelerator

Speaker: Pat Donahue, MBA

²²⁵Ac Production on an Electron Beam Accelerator

Speaker: James T. Harvey, PhD

DOE Development Work on New Therapeutic Radionuclides

Speaker: Cathy Cutler, PhD

Product Quality Considerations in Ac-225 Radiopharmaceuticals

Speaker: Ravi Kasliwal, PhD

Sunday, March 6, 2022

All session times are in Mountain Time

6:30 AM – 7:00 AM

Breakfast with the Sponsors

7:00 AM – 9:30 AM

Virtual & CE Session

Contemporary Nuclear Cardiology

Session Chair: Robert Hendel, MD

Co-Moderator: Daniel Berman, MD

Description: Changing guidelines and emerging evidence has increased the use of other modalities in coronary artery disease, thereby altering the use of nuclear cardiology techniques. This session will discuss the impact of changes and examine the role of contemporary nuclear cardiology, including expansion beyond traditional myocardial perfusion imaging.

Scheduled Topics:

Challenges from Recent Multimodality Literature and Updated Practice Guidelines

Speaker: Leslee Shaw, PhD

Myocardial Perfusion and Flow with PET: Global myocardial blood flow and assessment of non-obstructive coronary disease

Speaker: Krishna Patel, MD

Beyond Myocardial Perfusion: Amyloidosis, Sarcoidosis, Infection

Speaker: Bob Hendel, MD

New Agents, Improved Techniques, Enhanced Applications

Speaker: Rob Miller, MD

Hybrid Imaging and Adjunctive Calcium Scoring: Adding atherosclerosis to ischemia

Speaker: Dan Berman, MD

1:00 PM – 3:00 PM

Roundtable: New Agents/Radionuclides

Moderator: Roy Brown, MBA

Scheduled Topics:

This roundtable will discuss new diagnostic and therapeutic radiopharmaceuticals which are on the horizon for nuclear medicine, and their accompanying radionuclides. The panel will also explore the supply of enriched stable isotopes necessary for these new radionuclides our industry will deploy in the next few years. The panelists include two *Hal O'Brien Rising Star Recipients* for 2022.

Speakers: James T. Harvey, PhD, Pat Donahue, MBA, MBA, Robert Miller, MD, Attila Feher, MD, PhD, Cathy Cutler, PhD. Amir Irvani, MD

4:00 PM – 6:30 PM

Focused AI Session: AI Application in Nuclear Medicine and Beyond: Nuts and Bolts

Session Chair: Piotr Slomka, PhD

Description: Novel developments in artificial intelligence applied to medical imaging are reported in scientific publications and translated for clinical applications. This session aims to describe and discuss in depth (nuts and bolts) a wide range of applications currently considered for clinical use in nuclear medicine and beyond.

Scheduled Topics:

AI in Cardiac CT

Speaker: Michelle Williams, MD

AI in Nuclear Cardiology

Speaker: Piotr Slomka, PhD

AI in Echocardiography

Speaker: David Ouyang, MD

AI for PET Image Enhancement

Speaker: Joyita Dutta, PhD

AI in Neuroradiology

Speaker: Greg Zaharchuk, PhD

7:00 PM – 9:00 PM

Sunday Night Reception & Hal O'Brien Rising Star Award Ceremony

Open to all in-person attendees with meeting registration. Additional tickets available for guests.

Monday, March 7, 2022

All session times are in Mountain Time

6:30 AM – 7:00 AM

Breakfast with the Sponsors

7:00 AM – 9:30 AM

Policy and Regulatory Updates

Session Chair: Ira Goldman

Scheduled Topics:

Healthcare Policy and "Drug Pricing" - Congress, Biden Administration & CMS

Speaker: Julia Bellinger, SNMMI

FDA Developments

Speaker: Libero Marzella, Ravindra Kasliwal and Danae Christodoulou

FDA Questions

ASNC - Legislative efforts to repeal AUC requirements (2023 delay; FY2022 Labor, HHS, Ed approps language)

The Fate of Alternative Payment Systems

Speaker: Kathy Flood, CEO, American Society of Nuclear Cardiology

Speaker: Kevin Donohoe, MD

General Discussion

1:00 PM – 3:00 PM

Roundtable: TBD

Moderator: TBD

Speakers: TBD

4:00 PM – 7:30 PM

Preparing for the Artificial Intelligence Revolution in Imaging

Session Chairs: Ernie Garcia, PhD and Hans Vija, PhD

Description: A major opportunity in nuclear medicine is the many significant AI applications that have recently been reported. AI applications are being reported along the entire imaging process from acquisition to image interpretation and reporting. Although some have, most applications have yet to make it to widespread commercial distribution due to the recency of their developments, most reported in 2020 and lack of widespread validation as well as challenging socio-economic issues. This session addresses the need to be prepared both technically and socio-economically to fully benefit from these and a tsunami of other AI applications that are coming. Specific socio-economic AI issues addressed in this session are the need for warehousing of well curated Big Data and the role that societies are playing as well as regulatory, legal, and ethical issues.

Scheduled Topics:

Imaging Databases for AI: Developing & Curating

Speaker: Piotr Slomka, PhD

AI Development Efforts by Professional Societies:

ACR AI-LAB, Data Science Institute

Speaker: Bibb Allen Jr., MD, FACR, Chief Medical Officer

The Rise of Collaborative Intelligence

Speaker: Ami B Bhatt, MD, FACC, Chief Innovation Officer

Navigating the FDA Clearance Process for AI Applications

Speaker: Richard Frank, MD, PhD, MITA representative

When does physician use of AI increase liability?

Speaker: Aileen Nielsen, JD

Ethical Considerations in AI

Speaker: Nabile Safdar, MD, MPH

Who owns patients' data? /SUMMARY

Speaker: Ernest V Garcia, PhD

Panel: Is the nuclear medicine industry prepared/preparing for the AI revolution?

Reps from: Mita, Siemens, Syntermed, MIMs, Pharm, others....(45 min)

Tuesday, March 8, 2022

All session times are in Mountain Time

6:30 AM – 7:00 AM

Breakfast with the Sponsors

7:00 AM – 9:30 AM

Pediatric Session

Chair: Frederick D. Grant, MD

Description: The practice of pediatric nuclear medicine utilizes the same radiopharmaceuticals as are available for adult nuclear medicine, but reflects differences in disease prevalence in children and the need to evaluate pediatric-specific diseases. This session will provide an update on the investigational use of radiopharmaceuticals to image pediatric brain tumors, to evaluate infants with congenital hyperinsulinism, and to treat neuroblastoma.

Scheduled Topics:

C11-Methionine for Brain Imaging

Speaker: Barry Shulkin, MD, St. Jude

F18-F-DOPA Brain

Speaker: Maria Ponisio, MD, Mallinckrodt

F-18-F-DOPA for Hypoglycemia

Speaker: Lisa States, MD, CHOP

I-131 MIBG Therapy

Speaker: Susan Sharp, MD, Cincinnati Children's

1:00 PM – 3:00 PM

Roundtable: Controversies at the Cutting Edge of NeuroNuclear Imaging (NNI)

Moderator: Dan Silverman

Scheduled Topics:

Considering issues aimed at generating some heat on a cold winter's day (and, ultimately, some light), such as --

How appropriate are the "Appropriate Use Criteria" for NNI?

Is brain SPECT a dying art (or a dead science)?

Wherefore art thou Aducanumab?

FDOPA -- if not now, when?

4:00 PM – 7:30 PM

FDA-Approved Brain PET Radiotracers: Identifying Appropriate Uses and Navigating Path to Reimbursement

Moderator: Dan Silverman, MD, PhD

Description: As we are now in our sixth decade of experience with PET imaging of regional brain biochemistry, it is fitting that the cerebrum is the human organ for which the largest number of FDA-approved PET tracers currently exists, with several more in the pipeline. Their collective clinical utilization nevertheless remains underwhelming. This session aims to provoke discussion from multiple perspectives on present limitations and future potential of the evidentiary base and reimbursement status of the FDA-approved brain-specific tracers.

Scheduled Topics:

Failure to Get Payer Reimbursement for Amyloid Imaging -- What Went Wrong?

Speaker: Dan Silverman, MD, PhD, University of California, Los Angeles

Speaker: Andrew Stephens, MD, PhD, Life Molecular Imaging

What Will Be Needed to Maximize Likelihood of Reimbursement for Tau PET?

Speaker: Andrew Stephens, MD, PhD, Life Molecular Imaging

Moderated Comments: Government Regulatory and Academic Perspectives

Progress of Disease-Modifying Therapies for Neurodegenerative Disorders

Speaker: Ana Franceschi, MD, PhD, The Feinstein Institutes for Medical Research, Neuro-PET Imaging, Lenox Hill Hospital

Panel Discussion

CME Statement



Physician (AMA-PRA Category 1 Credits™):

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Society of Nuclear Medicine and Molecular Imaging, Inc. (SNMMI) and the High Country Nuclear Medicine Conference. The SNMMI is accredited by the ACCME to provide continuing medical education for physicians.

The Society of Nuclear Medicine and Molecular Imaging, Inc. (SNMMI) designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



The SNMMI, through its Verification of Involvement in Continuing Education (VOICE) program, has approved this meeting for a maximum of 5.0 continuing education hours (CEHs). VOICE-approved credit is recognized by most licensure states and by the NMTCB and ARRT as Category A+ credit. Participants must attend the entire session to receive CE credit. CA Scope information follows below.